NCT05567588 - Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions

Clear-cell Metastatic Renal Cell Carcinoma

Interventions

COMBINATION_PRODUCT

Drug: Pembrolizumab

200mg(body weight \>75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.

Trial Locations (2)

Unknown

RECRUITING

Guozhu,Xie, Guangzhou

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors

lead

Nanfang Hospital, Southern Medical University

OTHER